| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |